SGD Pharma Details Latest Sustainability Investments at DCAT Week 2025

TOP NEWS on grunge world map | Image Credit: © Sean K - stock.adobe.com

France-based SGD Pharma is using its presence at the Drug, Chemical & Associated Technologies Association (DCAT) Week 2025 to demonstrate how its multi-million-Euro investments in the next generation of glass manufacturing are impacting sustainability and innovation in the pharmaceutical industry (1).

Modernization of SGD Pharma’s global manufacturing sites, which the company discussed in a press release issued during DCAT Week on March 19, 2025, is a priority that was previously outlined by the company as part of its exhibition at CPHI Milan in October 2024 (1,2). At that conference, not only did SGD Pharma introduce a line of siliconized molded glass vials, but it also announced a €5 million (US$5.5 million) investment in the siliconization production line at its state-of-the-art Saint-Quentin Lamotte plant, in France (2).

That line is now operational, according to SGD Pharma’s DCAT Week update, and provides customers the availability of a glass treatment that the company says is a protective barrier for sensitive, aggressive, and/or viscous drug products (1). SGD Pharma is also highlighting its IDENCY Type I glass vials and Sterinity EZ-Fill ready-to-use offerings, both of which had been part of the CPHI Milan exhibit (1,2).

Velocity Vials, meanwhile, which were developed in conjunction with Corning, have a friction-reducing outer coating that SGD Pharma said can improve manufacturing efficiency by up to 50% (1).

Fabio Invernizzi, general manager, Business Unit West, and Carole Grassi Mircich, chief commercial marketing and innovation officer, will be SGD Pharma’s on-site representatives at DCAT Week 2025 (1),

“I am excited to attend DCAT Week and reconnect with our valued customers and partners,” Grassi Mircich said in the press release (1). “We are eager to dive deep into understanding their evolving needs, showcase our cutting-edge innovations, and explore new opportunities for collaboration that will drive the future of our industry.”

Grassi Mircich previously spoke with Pharmaceutical Technology® about SGD Pharma’s progress in packaging advancements in the October 2024 issue.

“During recent years, the demand for sustainability has accelerated throughout the packaging industry and has had a particular influence on the pharmaceutical industry,” Grassi Mircich said in the article. “Consumers are now more environmentally conscious than ever before, and sustainability has become a key factor in their decision-making. In a recent survey, FEVE [the European Container Glass Federation] revealed that three out of four European consumers find that purchasing sustainable products makes a difference for our environment ... Glass is already a highly sustainable packaging material and is [now] 70% less energy intensive than 50 years ago. However, in response to growing consumer demand, the glass packaging industry is striving to improve this further, investing around €600 million [US$670 million] each year on updates to manufacturing facilities and steps in the supply chain to improve energy efficiency.”

Click here for more coverage of DCAT Week 2025.

References

1. SGD Pharma. SGD Pharma Advances Sustainable Manufacturing and Supply Chain Innovation at DCAT Week 2025 in New York. Press Release. March 19, 2025.
2. SGD Pharma. New Labservices for Pharmaceutical Molded and Tubular Glass, Available Exclusively to SGD Pharma Customers and Partners. sgd-pharma.com/labservices (accessed Oct. 2, 2024).
3. Thomas, F. Out-of-the-Box Packaging Advancements. Pharmaceutical Technology 2024, 48 (10) 10–14.